Hot Features
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, ... Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 1750 | 9.811E-5 | CS |
| 26 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 948 | 9.681E-5 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0002 | 1.0E-6 | 1750 | 0.0001295 | CS |
| 156 | -9.9E-5 | -99 | 0.0001 | 0.0002 | 1.0E-6 | 1283 | 0.00010815 | CS |
| 260 | -0.184999 | -99.9994594595 | 0.185 | 0.375 | 1.0E-6 | 2302 | 0.08892175 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.